ocedurenone   Click here for help

GtoPdb Ligand ID: 12040

Synonyms: Example 12 [US9468635B2] | KBP-5074 | KBP5074
Compound class: Synthetic organic
Comment: Ocedurenone (KBP-5074) is a selective and potent non-steroidal mineralocorticoid receptor (MR) antagonist that was developed by KBP Biosciences for management of uncontrolled/resistant hypertension in advanced chronic kidney disease [3]. The non-steroidal MR antagonist class of drugs includes finerenone and esaxerenone which are already in clinical use. These agents typically demonstrate a lower risk of inducing hyperkalemia [2,5] and with reduced hormonal side effects compared to steroidal MR antagonists such as spironolactone and eplerenone.
The chemical structure for KBP-5074 that's depicted here, was disclosed in [3], and is the (3S,3aR) enantiomer, and this matches the structure submitted for the INN ocedurenone. This chemical structure is one of those claimed in KBP Biosciences' patent US9468635B2 (Example 12 therein) [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

ocedurenone is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 92.82
Molecular weight 503.21
XLogP 4.42
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES N#Cc1ccc(cc1Cl)N1N=C2[C@@H]([C@@H]1C1CCCC1)CCc1c2ccc(n1)C(=O)N1CCC(CC1)O
Isomeric SMILES C1CCC(C1)[C@H]1[C@H]2CCc3c(C2=NN1c1cc(c(cc1)C#N)Cl)ccc(n3)C(=O)N1CCC(CC1)O
InChI InChI=1S/C28H30ClN5O2/c29-23-15-19(6-5-18(23)16-30)34-27(17-3-1-2-4-17)22-8-9-24-21(26(22)32-34)7-10-25(31-24)28(36)33-13-11-20(35)12-14-33/h5-7,10,15,17,20,22,27,35H,1-4,8-9,11-14H2/t22-,27-/m0/s1
InChI Key UXHQLGLGLZKHTC-CUNXSJBXSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B et al.. (2021)
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study.
Hypertension, 78 (1): 74-81. [PMID:33966452]
2. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C et al.. (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
JAMA, 314 (9): 884-94. [PMID:26325557]
3. Chow CP, Liu JR, Tan XJ, Huang ZH. (2017)
Pharmacological Profile of KBP-5074, a Novel NonSteroidal Mineralocorticoid Receptor Antagonist for the Treatment of Cardiorenal Diseases.
ournal of Drug Research and Development, 3 (2). DOI: 10.16966/2470-1009.137
4. Huang Z, Wang J, Zhang D. (2016)
Fused ring compound for use as mineralocorticoid receptor antagonist.
Patent number: US9468635B2. Assignee: KBP Biosciences Co Ltd. Priority date: 18/08/2010. Publication date: 18/10/2016.
5. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. (2013)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Eur Heart J, 34 (31): 2453-63. [PMID:23713082]